Evidence map›Paper›PMID 31350616›Full record

ArticleApplied microbiology and biotechnology2019

Germinality does not necessarily define mAb expression and thermal stability.

Linda Schwaigerlehner, Patrick Mayrhofer, Matthias Diem, Willibald Steinfellner, Emma Fenech, Chris Oostenbrink, Renate Kunert

Open access · hybridAbstract read
In one paragraph

Article in Applied microbiology and biotechnology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.2field-weighted citation impact, top 47% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 2 countries.

Linda SchwaigerlehnerDepartment of Biotechnology, University of Natural Resources and Life Sciences, Muthgasse 18, 1190, Vienna, Austria.
Patrick MayrhoferDepartment of Biotechnology, University of Natural Resources and Life Sciences, Muthgasse 18, 1190, Vienna, Austria. patrick.mayrhofer@boku.ac.at.ORCID http://orcid.org/0000-0003-4763-5911
Matthias DiemDepartment of Material Sciences and Process Engineering, University of Natural Resources and Life Sciences, Muthgasse 18, 1190, Vienna, Austria.
Willibald SteinfellnerDepartment of Biotechnology, University of Natural Resources and Life Sciences, Muthgasse 18, 1190, Vienna, Austria.
Emma FenechLudwig Institute for Cancer Research, University of Oxford, Oxford, UK.
Chris OostenbrinkDepartment of Material Sciences and Process Engineering, University of Natural Resources and Life Sciences, Muthgasse 18, 1190, Vienna, Austria.
Renate KunertDepartment of Biotechnology, University of Natural Resources and Life Sciences, Muthgasse 18, 1190, Vienna, Austria.
BOKU University · ATUniversity of Oxford · GB

Funding

Austrian Science Fund W1224Austrian Science Fund FWF W 1224
6 · The paper itself

Abstract

The production potential of recombinant monoclonal antibody (mAb) expressing cell lines depends, among other factors, on the intrinsic antibody structure determined by the amino acid sequence. In this study, we investigated the influence of somatic mutations in the V(D)J sequence of four individual, mature model mAbs on the expression potential. Therefore, we defined four couples, each consisting of one naturally occurring mAb (2G12, Ustekinumab, 4B3, and 2F5) and the corresponding germline-derived cognate mAb (353/11, 554/12, 136/63, and 236/14). For all eight mAb variants, recombinant Chinese hamster ovary (CHO) cell lines were developed with mAbs expressed from a defined chromosomal locus. The presented workflow investigates critical parameters including productivity, intra- and extracellular product profile, XBP1 splicing, thermal stability, and in silico hydrophobicity. Significant differences in productivity were even observed between the germline-derived mAbs which did not undergo somatic mutagenesis. Accordingly, back-to-germline mutations of mature mAbs are not necessarily reflecting improved expression and stability but indicate opportunities and limits of mAb engineering. From our studies, we conclude that germinalization represents a potential to improve mAb properties depending on the antibody's germline family, highlighting the fact that mAbs should be treated individually.

Indexed as

Germ-Line MutationTemperatureAmino Acid SequenceAnimalsAntibodies, MonoclonalCHO CellsCricetinaeCricetulusMutationProtein StabilityRecombinant ProteinsAntibodies, MonoclonalRecombinant ProteinsDifficult to expressGerminalizationMammalian expression systemRecombinant antibody productionSecretory pathway

Identifiers

PMID31350616
PMCPMC6719414
OpenAlexW2966161802

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.